• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Bristol-Myers Squibb (NY:BMY)

    56.63 -1.50 (-2.57%)
    Streaming Delayed Price Updated: 11:05 AM EDT, Jul 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,365,759
    Open 57.74
    Bid (Size) 56.63 (300)
    Ask (Size) 56.65 (600)
    Prev. Close 58.13
    Today's Range 56.55 - 58.11
    52wk Range 42.52 - 62.89
    Shares Outstanding 2,222,113,553
    Dividend Yield 4.45%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Is Bristol Myers Squibb's 4.3% Dividend Yield Safe? Here's What Investors Need to Know. ↗
    This big pharma stock looks attractive for income investors -- but it comes with some risk. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Vanguard Is Bullish on Value Stocks and Fixed Income. Are These 2 ETFs a Good Buy? ↗
    Strong productivity gains from AI -- and lower inflation -- could be good news for these Vanguard ETFs. 
    Via The Motley Fool
    Topics Artificial Intelligence Bonds ETFs

    Performance

    YTD
    +5.9%
    +5.9%
    1 Month
    -1.1%
    -1.1%
    3 Month
    -4.5%
    -4.5%
    6 Month
    +6.7%
    +6.7%
    1 Year
    +21.8%
    +21.8%

    More News

    Read More
    News headline image
    2 Cash-Producing Stocks Worth Investigating and 1 Facing Headwinds
    Via StockStory
    Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Play with Cautionary Notes ↗
    Via Chartmill
    Bristol-Myers Squibb Co (NYSE:BMY): High Yield and Solid Profitability, but Growth Concerns Loom ↗
    Via Chartmill
    News headline image
    Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? ↗
    Via The Motley Fool
    News headline image
    Rolling Into Spreads: Extend Profit Potential with Lower Risk ↗
    Via InvestorPlace
    News headline image
    3 Unpopular Stocks with Questionable Fundamentals
    Via StockStory
    News headline image
    Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? ↗
    Via The Motley Fool
    InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
    Via Investor Brand Network
    News headline image
    The Quest to Repair What Multiple Sclerosis Takes Away
    From BioMedWire
    Via GlobeNewswire
    News headline image
    3 Reasons to Buy Bristol Myers Squibb Stock ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    1 S&P 500 Stock with Solid Fundamentals and 2 We Avoid
    Via StockStory
    Topics Stocks
    News headline image
    Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026
    From Bristol Myers Squibb
    Via Business Wire
    News headline image
    Bristol Myers Squibb Announces Dividend
    From Bristol Myers Squibb
    Via Business Wire
    News headline image
    3 Dividend Stocks to Hold for the Long Haul ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take. ↗
    Via The Motley Fool
    Topics Bonds Intellectual Property
    News headline image
    Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue. ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease
    From Bristol Myers Squibb
    Via Business Wire
    News headline image
    Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500? ↗
    Via The Motley Fool
    Topics Intellectual Property Stocks
    News headline image
    Billionaire Izzy Englander Just Made a Big Bet on This Beaten-Down High-Yield Dividend Stock ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer? ↗
    Via The Motley Fool
    News headline image
    3 Value Stocks We Think Twice About
    Via StockStory
    News headline image
    Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now? ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma
    From Bristol Myers Squibb
    Via Business Wire

    Frequently Asked Questions

    Is Bristol-Myers Squibb publicly traded?
    Yes, Bristol-Myers Squibb is publicly traded.
    What exchange does Bristol-Myers Squibb trade on?
    Bristol-Myers Squibb trades on the New York Stock Exchange
    What is the ticker symbol for Bristol-Myers Squibb?
    The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
    What is the current price of Bristol-Myers Squibb?
    The current price of Bristol-Myers Squibb is 56.63
    When was Bristol-Myers Squibb last traded?
    The last trade of Bristol-Myers Squibb was at 07/06/26 11:05 AM ET
    What is the market capitalization of Bristol-Myers Squibb?
    The market capitalization of Bristol-Myers Squibb is 125.85B
    How many shares of Bristol-Myers Squibb are outstanding?
    Bristol-Myers Squibb has 126B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.